Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)

Tipranks - Tipranks - Wed Apr 1, 6:56AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH).

End of Quarter Sale - 50% Off TipRanks

MoonLake Immunotherapeutics (MLTX)

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $33.00. The company’s shares closed last Monday at $16.93.

According to TipRanks.com, Katkhuda is a 5-star analyst with an average return of 32.0% and a 53.8% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Amylyx Pharmaceuticals Inc, and Maze Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MoonLake Immunotherapeutics with a $28.57 average price target, a 65.5% upside from current levels. In a report issued on March 19, Rothschild & Co Redburn also upgraded the stock to Buy with a $40.00 price target.

See the top stocks recommended by analysts >>

Neumora Therapeutics, Inc. (NMRA)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $6.00. The company’s shares closed last Monday at $1.93, close to its 52-week low of $1.02.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 19.5% and a 47.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and EyePoint Pharmaceuticals. ;'>

Neumora Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $10.80, implying a 402.3% upside from current levels. In a report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $14.00 price target.

Aurinia Pharmaceuticals (AUPH)

Bloom Burton analyst David Martin PhD maintained a Hold rating on Aurinia Pharmaceuticals today and set a price target of $15.00. The company’s shares closed last Monday at $13.98.

According to TipRanks.com, PhD is a 5-star analyst with an average return of 16.9% and a 49.8% success rate. PhD covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, Helus Pharma, and Zymeworks. ;'>

Aurinia Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.

Read More on MLTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).